Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H16ClNO2S.ClH |
Molecular Weight | 358.283 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.COC(=O)[C@@H](N1CCC2=C(C1)C=CS2)C3=CC=CC=C3Cl
InChI
InChIKey=XIHVAFJSGWDBGA-RSAXXLAASA-N
InChI=1S/C16H16ClNO2S.ClH/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14;/h2-5,7,9,15H,6,8,10H2,1H3;1H/t15-;/m0./s1
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C16H16ClNO2S |
Molecular Weight | 321.822 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopidogrel is sold under the name Plavix by Sanofi and Bristol-Myers Squibb. Plavix (clopidogrel bisulfate) is an inhibitor of ADP-induced platelet aggregation acting by direct
inhibition of adenosine diphosphate (ADP) binding to its receptor and of the subsequent ADPmediated
activation of the glycoprotein GPIIb/IIIa complex. Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that
inhibits platelet aggregation. The active metabolite of clopidogrel selectively inhibits the
binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADPmediated
activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet
aggregation. This action is irreversible. Consequently, platelets exposed to clopidogrel’s active
metabolite are affected for the remainder of their lifespan (about 7 to 10 days). Platelet
aggregation induced by agonists other than ADP is also inhibited by blocking the amplification
of platelet activation by released ADP. Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
6.9 null [pKi] | |||
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PLAVIX Approved UsePlavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as
follows:
• Recent MI, Recent Stroke or Established Peripheral Arterial Disease
For patients with a history of recent myocardial infarction (MI), recent stroke, or established
peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint
of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.
• Acute Coronary Syndrome
-For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave
MI) including patients who are to be managed medically and those who are to be
managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix
has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or
stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or
refractory ischemia.
Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as
follows:
• Recent MI, Recent Stroke or Established Peripheral Arterial Disease
For patients with a history of recent myocardial infarction (MI), recent stroke, or established
peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint
of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.
• Acute Coronary Syndrome
-For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave
MI) including patients who are to be managed medically and those who are to be
managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix
has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or
stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or
refractory ischemia. Launch Date1997 |
|||
Primary | PLAVIX Approved UsePlavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as
follows:
• Recent MI, Recent Stroke or Established Peripheral Arterial Disease
For patients with a history of recent myocardial infarction (MI), recent stroke, or established
peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint
of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.
• Acute Coronary Syndrome
-For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave
MI) including patients who are to be managed medically and those who are to be
managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix
has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or
stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or
refractory ischemia. Launch Date1997 |
|||
Primary | PLAVIX Approved UsePlavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as
follows:
• Recent MI, Recent Stroke or Established Peripheral Arterial Disease
For patients with a history of recent myocardial infarction (MI), recent stroke, or established
peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint
of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.
• Acute Coronary Syndrome
-For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave
MI) including patients who are to be managed medically and those who are to be
managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix
has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or
stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or
refractory ischemia. Launch Date1997 |
|||
Preventing | PLAVIX Approved UsePlavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as
follows:
• Recent MI, Recent Stroke or Established Peripheral Arterial Disease
For patients with a history of recent myocardial infarction (MI), recent stroke, or established
peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint
of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.
• Acute Coronary Syndrome
-For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave
MI) including patients who are to be managed medically and those who are to be
managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix
has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or
stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or
refractory ischemia. Launch Date1997 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.521 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT02185534 |
75 mg single, oral dose: 75 mg route of administration: oral experiment type: single co-administered: |
CLOPIDOGREL plasma | Homo sapiens population: healthy age: sex: food status: |
|
15800 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
4600 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2520 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
1500 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.09 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT02185534 |
75 mg single, oral dose: 75 mg route of administration: oral experiment type: single co-administered: |
CLOPIDOGREL plasma | Homo sapiens population: healthy age: sex: food status: |
|
0.767 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT02185534 |
75 mg single, oral dose: 75 mg route of administration: oral experiment type: single co-administered: |
CLOPIDOGREL plasma | Homo sapiens population: healthy age: sex: food status: |
|
50600 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
9890 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
7440 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
3130 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
7.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
7.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
8.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2% |
unknown, unknown |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
600 mg 1 times / day multiple, oral Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
healthy, 20-45 years |
Other AEs: Uric acid abnormal... |
1650 mg single, oral Overdose |
unknown, 49 years |
|
600 mg 1 times / day multiple, oral Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 59 years |
Disc. AE: Transaminases increased, Fever... AEs leading to discontinuation/dose reduction: Transaminases increased (1 patient) Sources: Fever (1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Uric acid abnormal | 5 patients | 600 mg 1 times / day multiple, oral Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
healthy, 20-45 years |
Fever | 1 patient Disc. AE |
600 mg 1 times / day multiple, oral Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 59 years |
Transaminases increased | 1 patient Disc. AE |
600 mg 1 times / day multiple, oral Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 59 years |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 169.0 |
no | |||
Page: 91, 169 |
no | |||
no | ||||
Page: 91, 169 |
no | |||
Page: 169.0 |
no | |||
Page: 91, 169 |
no | |||
Page: 169.0 |
no | |||
Page: 91, 169 |
no | |||
Page: 169.0 |
no | |||
Page: 91, 169 |
no | |||
Page: 169.0 |
no | |||
Page: 91, 169 |
no | |||
Page: 74.0 |
no | |||
weak | ||||
weak | ||||
yes [IC50 0.307 uM] | ||||
yes [IC50 6.25 uM] | ||||
Page: 91, 170 |
yes [Ki 28 uM] | |||
yes | ||||
Page: 22.0 |
yes | |||
yes | ||||
Page: 74.0 |
yes | |||
Page: 74.0 |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 168.0 |
likely | |||
Page: 168.0 |
likely | |||
Page: 168.0 |
likely | |||
Page: 168.0 |
no | |||
Page: 168.0 |
no | |||
no | ||||
no | ||||
no | ||||
no | ||||
yes [Km 181 uM] | ||||
yes [Km 19 uM] | ||||
yes [Km 20.9 uM] | ||||
yes [Km 5.61 uM] | ||||
yes | ||||
Page: 168.0 |
yes | |||
Page: 168.0 |
yes | |||
Page: 168.0 |
yes | |||
yes | ||||
Page: 74.0 |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Effect of clopidogrel on naproxen-induced gastrointestinal blood loss in healthy volunteers. | 1998 |
|
Drug-induced thrombotic microangiopathy: incidence, prevention and management. | 2001 |
|
Atherothrombosis: a major health burden. | 2001 |
|
Novel platelet inhibitors. | 2001 |
|
Antithrombotic drugs for secondary stroke prophylaxis. | 2001 Apr |
|
Results of CURE trial for acute coronary syndrome. | 2001 Apr 11 |
|
Key role of the P2Y(1) receptor in tissue factor-induced thrombin-dependent acute thromboembolism: studies in P2Y(1)-knockout mice and mice treated with a P2Y(1) antagonist. | 2001 Feb 6 |
|
Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo. | 2001 Jan |
|
Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. | 2001 Jan 23 |
|
Febrile pancytopenia associated with clopidogrel. | 2001 Jan 8 |
|
Clopidogrel (Plavix): hematological reactions. | 2001 Jan 9 |
|
The role of adenosine 5'-diphosphate receptor blockade in patients with cardiovascular disease. | 2001 Jul |
|
Diffuse alveolar hemorrhage after clopidogrel use. | 2001 Jul |
|
Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population. | 2001 Jul 31 |
|
Orbofiban: an orally active GPIIb/IIIa platelet receptor antagonist. | 2001 May |
|
Antiplatelet agents for secondary prevention of ischemic stroke. | 2001 Oct |
|
Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. | 2001 Sep |
Sample Use Guides
Recent MI, Recent Stroke, or Established Peripheral Arterial Disease
The recommended daily dose of is 75 mg once daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10077233
Incubation of human washed platelets with clopidogrel resulted in a time- (maximum effects after 30 min) and concentration-dependent (IC50 1.9+/-0.3 uM) inhibition of ADP (6 uM)-induced platelet aggregation. Clopidogrel (30 uM) did not inhibit collagen (2.5 ug ml(-1))-, U46619 (1 uM)- or thrombin (0.1 u ml(-1))-induced platelet aggregation.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:57:39 GMT 2025
by
admin
on
Mon Mar 31 18:57:39 GMT 2025
|
Record UNII |
426O7XWS6Y
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL KRKA (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL-TAD (AUTHORIZED: STROKE)
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL TEVA GENERICS B.V. (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL-HCS (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL KRKA D.D. (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL KRKA (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL TEVA PHARMA (AUTHORIZED: STROKE)
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL TAD (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL-HCS (AUTHORIZED: STROKE)
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL DURA (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL QUALIMED (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL TEVA GENERICS B.V. (WITHDRAWN: ACUTE CORONARY SYNDROME)
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL QUALIMED (WITHDRAWN: STROKE)
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL-DURA (WITHDRAWN: STROKE)
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL MYLAN (AUTHORIZED: STROKE)
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL TEVA PHARMA (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL TEVA GENERICS B.V. (WITHDRAWN: STROKE)
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL KRKA D.D. (AUTHORIZED: STROKE)
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL-KRKA (AUTHORIZED: STROKE)
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL KRKA D.D. (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL QUALIMED (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL TEVA GENERICS B.V. (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL DURA (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
||
|
NCI_THESAURUS |
C80483
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL TEVA PHARMA (AUTHORIZED: AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL-HCS (AUTHORIZED: ACUTE CORONARY SYNDROME)
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL MYLAN (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL TAD (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL HCS (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL MYLAN (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DBSALT002594
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
PRIMARY | |||
|
100000115888
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
PRIMARY | |||
|
120202-65-5
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
PRIMARY | |||
|
9798860
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
PRIMARY | |||
|
426O7XWS6Y
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
PRIMARY | |||
|
C96893
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
PRIMARY | |||
|
SUB30779
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
PRIMARY | |||
|
DTXSID40152734
Created by
admin on Mon Mar 31 18:57:39 GMT 2025 , Edited by admin on Mon Mar 31 18:57:39 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |